Advanced Lung Squamous Carcinoma
Conditions
Keywords
Endostar,Advanced lung squamous carcinoma
Brief summary
Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance treatment., and explore the predicted biomarkers.
Interventions
BIOLOGICALEndostar
Endostar 30mg continuous intravenous injection pump,d1-d7；
DRUGDocetaxel
d4 Docetaxel，75（mg/m2），iv；
DRUGCisplatin
d4，cisplatin，75（mg/m2），iv；
Sponsors
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Cytological and histological confirmation（Do not accept single sputum cytology in the diagnosis of patients） in patients diagnosed of lung squamous carcinoma; 2. According to a new IASLC2009 lung cancer TNM stages judged stage IIIB or IV non-small cell lung cancer. 3. Must have at least one evaluated lesion,according to the RRECIST version 1.1 standard (the longest diameter on spiral CT at least 10 mm,the longest diameter on plain CT at least 20 mm); 4. Male or female, age between 18 and 75 years old ; 5. ECOG PS 0\ 1； 6. Expected survival period ≥ 3 months or more 7. Enough blood function: absolute neutrophil count (ANC)≥2 x 109 / L and the platelet count≥ 100 x 109 / L and hemoglobin ≥9 g/dL; 8. Enough liver function: total bilirubin acuities≤the upper limit of normal (ULN); AST and ALT acuities ≤2.5 times of the upper limit of normal (ULN); Alkaline phosphatase ≤5 times of the upper limit of normal(ULN); 9. Enough renal function：serum creatinine ≤the limit of normal(ULN) or calculated creatinine clearance≥60 mL/min. 10. The electrocardiogram (ecg) basicaly normal,the body had no to heal wounds 11. No previous anti-tumor drug therapy, or only received for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the study start. 12. Patients had surgery before,but have more than 4 weeks before the study star, and the patient has recovered; 13. Women with cmpleted uterus before intact in the group within 28 days must have a negative pregnancy test results (unles amenorrhea for 24 months). If the pregnancy test from the first time for more than 7 days,the patients need for urine pregnancy test(within 7 days before the first delivery). 14. Prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions; 15. Sign the informed consent.
Exclusion criteria
1. Pregnancy, nursing mothers, or female patients with fertility but no contraception. 2. Existing serious acute infection, and can not be controlled; Or with fester sex and chronic infection,or wound in delay; 3. Original serious heart disease, including: congestive heart failure, uncontroled high risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension; 4. With uncontroled nerve, mental illness or mental disorders, compliance is poor, can't cooperate and response to treatment; Uncontroled primary brain tumors or CNS metastases illness, with obvious symptoms in cranial hypertension or nerve spirit; 5. With a bleeding tendency 6. Researchers believe that patients should not participate in this test.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | up to month 36 | FS is a tumor progression or death time of a patient who has an objective record on the date of enrollment. PFS calculation end if the patient was lost, unknow death , or other anti tumor therapy was used. |
Secondary
| Measure | Time frame |
|---|---|
| overall remission rate(ORR) | change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase. |
| Disease control rate （DCR） | change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase. |
| Overall survival（OS） | change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase. |
Countries
China
Contacts
Primary ContactYin Qingfeng, manager
Backup ContactZhou Xiaolei, sponsor
Outcome results
None listed